低剂量锂-卡比马唑治疗甲状腺毒症

Low dose lithium-carbimazole in the treatment of thyrotoxicosis.

作者信息

Hedley J M, Turner J G, Brownlie B E, Sadler W A

出版信息

Aust N Z J Med. 1978 Dec;8(6):628-30. doi: 10.1111/j.1445-5994.1978.tb04852.x.

DOI:10.1111/j.1445-5994.1978.tb04852.x

Abstract

Fifteen patients with thyrotoxicosis were treated with low dose sustained release lithium carbonate 400 mg, combined with carbimazole 40 mg daily, and the therapeutic response was followed over a two week period. This response was compared with that obtained in a similar group of patient treated with carbimazole alone. Li-carbimazole treatment brought about a fall in the mean total serum T4 of 57.4% compared with a drop of 32.8% in patients treated with carbimazole alone. The mean serum T3 fell by 69.4% in the Li-carbimazole group compared with 47.3% in the group treated with carbimazole only. No lithium adverse effects were encountered.

摘要

15例甲状腺毒症患者接受低剂量缓释碳酸锂400毫克治疗，每日联合40毫克卡比马唑，在两周内观察治疗反应。将此反应与另一组仅接受卡比马唑治疗的相似患者群体的反应进行比较。与仅接受卡比马唑治疗的患者血清总T4平均下降32.8%相比，锂 - 卡比马唑治疗使血清总T4平均下降了57.4%。锂 - 卡比马唑组血清T3平均下降69.4%，而仅接受卡比马唑治疗的组下降47.3%。未发现锂的不良反应。